Previous Close | 3.9000 |
Open | 3.9000 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 7.50 |
Expire Date | 2024-07-19 |
Day's Range | 3.9000 - 3.9000 |
Contract Range | N/A |
Volume | |
Open Interest | 162 |
Even if it's not a huge purchase, we think it was good to see that Burke Barrett, the President & CEO of Pulse...
HAYWARD, Calif., May 20, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE) ("Pulse" or the "Company"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced that the Company’s Board of Directors has determined a new record date for the Company’s previously announced rights offering (the "Rights Offering"), which will be available to all holders of record of the Company’s common stock, par value $0.001 per share (the "Common Stock
HAYWARD, Calif., May 16, 2024--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced CellFX nsPFA technology will be featured in multiple presentations at the upcoming Heart Rhythm Society (HRS) 2024 Annual Meeting in Boston, MA from May 16-19.